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Removing Breast Cancer's Roots
Cancer stem cells or cancer-initiating cells are a major therapeutic barrier because they have the potential to initiate tumor growth with only a small population of cells. Although some cancer therapies can stabilize the growth of this unique population, these cells are highly resistant to apoptosis induced by both chemo-and radiotherapy. Now, Lang et al. present a new strategy for killing these cells and for increasing their susceptibility to chemotherapy, thus lowering the chance that the tumor will return.
Current chemotherapies for breast cancer disrupt pathways needed for cancer growth, resulting in apoptosis of cancer cells. It is thought that breast cancer-initiating cells evade these types of treatment because they overexpress antiapoptotic proteins. Lang et al. demonstrate that expression of a constitutively active mutant of the proapoptotic protein Bik (BikDD) can overcome the protective effect of the antiapoptotic proteins. To target BikDD to breast cancer cells, Lang et al. identify a promoter that is highly expressed in breast cancer using published expression data. They also take advantage of an innovative gene therapy vector that increases and sustains transgene expression in cancer cells, selectively expressing BikDD at high levels both in cells and in mice with virtually no toxicity.
Although BikDD expression potently kills breast cancer-initiating cells on its own, this therapy is even more effective when used in combination with small-molecule chemotherapeutics. This synergistic activity reduces the growth rate of tumors in xenograft mouse models even weeks after cessation of therapy. These data suggest a promising strategy to eliminate breast cancerinitiating cells with few side effects, even in patients whose previous cancer treatments were unsuccessful.
Lang, J-Y., et al. (2011). Cancer Cell 20, 341-356.
Luciferase imaging of mice after tail vein injection with DNA plasmid liposomes demonstrates that the engineered vector (VISA-claudin4-Luc) is selectively expressed in tumor, but not in normal, tissues, whereas a nonspecific vector (CMVLuc) was primarily expressed in normal lung, the first targeting tissue after tail vein injection.
Bispecific T cells are created by the introduction of genes that encode the heterodimeric T cell receptor (top) or chimeric antigen receptors (CARs) that target surface antigens in an MHC-independent fashion (bottom) (LAT, linker for activation of T cells; ScFv, single-chain variable fragment; ZAP70, zeta chainassociated protein kinase 70 kDa). Image courtesy of C. June.
Help for Ailing Hearts
In patients with heart failure, the heart cannot pump enough blood throughout the body. The heart attempts to compensate for its inefficiency, leading to a progressive loss of myocardial tissue and numerous physiological changes. Most conventional therapies treat a patient's symptoms and help ameliorate disease, but they fail to reverse the progression of the disease. Now, Pleger et al. take a step closer to treating the causes of progressive heart failure with gene therapy. The authors demonstrate the safety and efficacy of using an adenoviral vector to deliver the Ca 2+ sensor protein, S100A1, in a pig model of chronic heart failure.
Previous results from gene therapy trials in rodents suggested that this method may be successful at restoring long-term cardiac function. However, given the differences between mice and humans in anatomy, physiology, and cardiac output, it was hard to assume that this therapy would be as effective in humans. Large animal models like the pig approximate the human cardiovascular system more closely, and they are critical for translating cardiac gene therapy to the clinic.
Pleger et al. experimentally trigger a myocardial infarction in the pigs, leading them to develop heart failure within weeks. They then demonstrate that a minimally invasive delivery system via a catheter can deliver therapeutically effective levels of engineered adeno-associated virus directly to the heart. To help ensure targeted expression in the heart, they place S100A1 under the control of a cardiomyocyte-specific promoter. Within months after infusion with the virus, expression of S100A1 rescues cardiac function, reverses cardiac enlargement, and restores Ca 2+ handling. Based on these data, gene therapy with S100A1 may move into clinical trials in patients with heart failure and hopefully reverse and prevent progression of this relentless disease. Pleger, S., et al. (2011). Sci. Transl. Med. 3, 92ra64. 
Poxvirus Poisons Cancers
Killing cancer cells with biological molecules, such as peptides, recombinant proteins, or small interfering RNAs, is an attractive therapeutic strategy because these molecules can potentially target pathways that small molecules cannot. However, treating solid tumors with molecules is effective only when they can be delivered efficiently and specifically to cancer tissues. Now, Breitbach et al. design an oncolytic poxvirus to express transgenes selectively in the solid tumors of patients. The idea is to exploit the natural ability of a virus to lyse and kill cells in which it replicates. Although simple in theory, achieving this requires innovative approaches.
Breitbach et al. use vaccinia virus (a poxvirus used in smallpox vaccines), as this enveloped virus is known for its ability to evade recognition by the immune system, traffic readily in the vasculature, and gain entry into a variety of cell types. To help the virus kill the tumor cells, the authors engineer it to express a cytokine, GM-CSF, that stimulates the immune system. The virus also decreases the tumor's blood supply. The key to ensuring that the virus replicates specifically inside of cancer cells is to delete the virus's thymidine kinase gene. This makes the virus dependent on the cell's supply of thymidine kinase, a downstream target of the EGFR/Ras pathway, which is overexpressed in cancer cells.
Breitbach and colleagues then test the therapy on 23 patients with nine different types of metastatic solid tumors refractory to conventional therapies. The patients receive a single intravenous injection of the engineered virus, which displays minimal toxicity regardless of the dose. The patients exhibit dose-dependent viral infectivity of the solid tumors, cancer cell-specific viral replication and transgene expression, and corresponding antitumor activity. Although the therapy is still in development (phase 2b), the broad potential of this strategy is clear. These poxviruses can be modified to express any transgene or short hairpin RNA that could promote tumor killing, making these viruses an ideal platform for future therapies. Breitbach, C., et al. (2011) . Nature 477, 99-104.
Representative echocardiographic images of a control and S100A1-treated pig heart demonstrate that S100A1 effectively prevents and reverses left ventricular dysfunction 3 months after cardiactargeted intravenous gene therapy. Image courtesy of Patrick Most, Sven Pleger, and Christophe Weber, Centre for Molecular and Translational Cardiology, Department of Medicine III, Heidelberg University, Germany.
Immunohistochemical staining for vaccinia in biopsy of patient with metastatic colorectal cancer 10 days following viral (JX-594) infusion demonstrates selective infection of tumor cells. Image courtesy of Caroline Breitbach and David Kirn.
